This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vertex Has the Potential to Go Vertical

Stocks in this article: VRTX

NEW YORK (TheStreet) -- After the entire biotech sector posted more than 60% gains in 2013, which more than doubled the performance of the S&P 500, there's little debate that biotech stocks were among the Street's favorites last year. In 2014, however, this means there are very few biotech bargains left. Yet Vertex Pharmaceuticals (VRTX) seems to fit that bill.

As intimately as I've followed this sector last year, I still can't forgive myself for passing up on this company. What I notice now is a company with a strong and distinguishing product portfolio that has the potential to dominate its market. And with a bit of luck in clinical trials, the company will be able to generate close to $6 billion to $10 billion in annual revenue.

Vertex's key drug is Kalydeco, used to fight cystic fibrosis in a relatively small group of patients with a specific genetic mutation. Unlike older drugs which only treat the symptoms of cystic fibrosis, Kalydeco is revolutionary because it addresses the underlying condition of the disease. Even better, the company's is making progress on developing additional cystic fibrosis drugs, which will be used in combinations to benefit larger groups of patients with other genetic mutations. What I like best about Vertex is that the company has the potential to corner the market for the treatment of a disease that is still lethal and remains one of the most common chronic lung illnesses in children and young adults.

The Street has caught on. Last year, Vertex shares rose almost 80%. Understandably investors are taking a more cautious, if not skeptical, approach to Vertex this year. The company's success in 2014 will hinge largely on the outcome of two clinical studies testing the combination of two cystic fibrosis drugs. The company is expected to announce results from these clinical studies in the middle of the year. While I can understand investors being worried about the result from this combination approach to treating cystic fibrosis, I don't believe this is the right time to lack confidence in Vertex's management.

[Read: Apple and IBM Have Must-See Charts]

On Wednesday, Vertex will report fourth-quarter and full-year 2013 earnings. The Street is looking for a loss of 38 cents per share on revenue of $229 million, which would represent a year-over-year revenue decline of 31%. Sales of Vertex's hepatitis C drug have declined due to competition from newer medicines in that disease, but investors are focusing more now on the company's cystic fibrosis drugs, which don't have near-term competition. Revenue and near-term profitability do not drive this stock. What's important for Vertex is the further development of its cystic fibrosis pipeline, and in that regard, I like Vertex.

All told, Vertex will be one of the best stocks to follow in biotech. And the results of the company's testing will certainly have a meaningful impact on growth expectations and where the stock ultimately goes. Although risks remain, absent a comparable alternative, the Street has no choice but to love Vertex for the foreseeable future.

At the time of publication, the author held no position in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs